Neurology & Brain Disorders Clinical Trials Update: Week 23, 2026

Published June 5, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

This large study is testing whether atorvastatin, a common cholesterol-lowering drug, can help reduce dementia, disability, and heart problems in older adults. By comparing atorvastatin to a placebo, researchers hope to find an accessible way to protect brain health and overall function as people age. The trial is underway across more than 100 sites in the United States and Puerto Rico, with results expected in the next few years.

Long-term Extension of Phase 3 Study of ALZ-801 in APOE4/4 Early AD Subjects

This trial is focusing on ALZ-801, a pill designed to slow cognitive decline in people with early Alzheimer’s disease who carry a specific genetic risk factor called APOE4/4. The study continues to follow participants long term to understand if this oral treatment can provide a simpler way to manage the disease. Results will help guide future treatment options for this group.

Comparing the Outcome of Buccal Midazolam and Intramuscular Midazolam in Children Presenting With Seizures

This completed trial compared two ways of giving midazolam, a medication used to stop seizures, to children experiencing seizures. The goal was to find a faster and easier method to improve emergency care for kids with seizure disorders. Results from the 90 participants will inform how medical teams treat seizures in pediatric patients going forward.

A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

This ongoing Phase 2 study is testing benfotiamine, an oral drug, to see if it can safely slow down cognitive decline in people with early Alzheimer's disease. The hope is that this treatment could improve thinking and daily functioning. The trial is active in several locations across the United States but is not currently recruiting new participants.

BCI With 40Hz Stimulation in Alzheimer's Disease

This study is exploring a non-drug approach using a brain-computer interface combined with 40Hz audio-visual stimulation to improve cognitive function in Alzheimer's patients. If effective, this treatment could offer a new option to slow memory and thinking problems without medication. The trial is recruiting participants in China and plans daily treatment over six months.

This week’s research reflects ongoing efforts to find treatments that slow cognitive decline and improve quality of life for those affected by neurological conditions. From drug therapies to innovative brain stimulation techniques, these trials offer hope for new ways to manage diseases like Alzheimer’s and seizure disorders. Continued progress depends on diverse studies like these moving through clinical testing.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.